524731 — Jenburkt Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapHigh Flyer

Annual income statement for Jenburkt Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,093	1,240	1,367	1,420	1,517
Cost of Revenue
Gross Profit	784	913	1,022	1,101	1,220
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	915	986	1,086	1,112	1,140
Operating Profit	178	254	281	308	377
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	216	299	329	352	439
Provision for Income Taxes
Net Income After Taxes	165	223	246	260	321
Net Income Before Extraordinary Items
Net Income	165	223	246	260	321
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	165	223	246	260	321
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	36	48.3	55.7	58.9	72.7
Dividends per Share